Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer-Reference-Cited by-同舟云学术

Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer

Published:2018-03 Issue:6 Volume:14 Page:537-544
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Ban Marija¹,Miše Branka Petrić¹,Majić Ana¹,Dražić Ivanka¹,Vrdoljak Eduard¹

Affiliation:

1. Department of Oncology & Radiotherapy, University Hospital Centre Split, Split School of Medicine, Spinčićeva 1, 21000 Split, Croatia

Abstract

Aim: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. Methods: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. Results: A total of 58.3% patients achieved stable disease. No objective response was observed. Median progression-free survival was 4.8 months; median overall survival was 11 months. Treatment was well tolerated. Conclusion: Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2017-0491

Reference24 articles.

1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

2. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

3. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer

4. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

5. Mechanisms of Endocrine Resistance in Breast Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer;Cancer Biology & Therapy;2023-10-13

2. Aspects biologiques, précliniques et cliniques de l’association de radiothérapie et d’inhibiteur de CDK 4/6;Cancer/Radiothérapie;2023-05

3. Efficacy and safety of palbociclib plus endocrine therapy for patients with HR+/HER2− advanced breast cancer in real-world clinical practice;Annals of Translational Medicine;2022-03

4. The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC;Clinical Breast Cancer;2021-10

5. Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study;Annals of Translational Medicine;2021-04